Answers are grounded in this paper and cite their sources.
Review reveals how cardiolipin abnormalities disrupt mitochondrial dynamics in neurodegenerative disorders, highlighting its promise as a biomarker and therapeutic target.
Cardiolipin (CL) is a mitochondria-exclusive phospholipid synthesized in the inner mitochondrial membrane. CL plays a key role in mitochondrial membranes, impacting a plethora of functions this organelle performs. Consequently, it is conceivable that abnormalities in the CL content, composition, and level of oxidation may negatively impact mitochondrial function and dynamics, with important implications in a variety of diseases. This review concentrates on papers published in recent years, combined with basic and underexplored research in CL. We capture new findings on its biological functions in the mitochondria, as well as its association with neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease. Lastly, we explore the potential applications of CL as a biomarker and pharmacological target to mitigate mitochondrial dysfunction.
No takes yet. Share an insight, caveat, or question.
Fuentes et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: